In the News

Date	Title
April 29, 2021	Outlook Therapeutics is bringing a treatment for retinal disease to the market at the right time
April 12, 2021	Outlook Therapeutics 'almost complete' with pivotal Phase 3 NORSE TWO trial to treat wet AMD
April 1, 2021	SUBSPECIALTY NEWS: Ophthalmic bevacizumab, add-on AMD therapy, gene therapy, and more
February 10, 2021	With New Clarity of Trial Data, Outlook Therapeutics Stock Rebounds
January 5, 2021	The Outlook on Getting Regulatory-Approved Bevacizumab to Market
December 9, 2020	Targeting Retinal Diseases with an Ophthalmic Formulation of Bevacizumab
October 6, 2020	Spotlight Q&A: Outlook Therapeutics - Developing First Ophthalmic Formulation of Bevacizumab for FDA Approval
January 7, 2019	Proactive Investors interview with Outlook Therapeutics CEO Larry Kenyon